By competitively inhibiting EGFR activation, cetuximab effectively blocks signal transduction pathways mediated by endogenous ligands, resulting in the suppression of tumor cell proliferation, inhibition of tumor angiogenesis and metastasis, and induction of apoptosis in malignant cells (10). The gene discussed is EGFR; the disease is neoplasm.